Cargando…

Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycemia in patients with type 2 diabetes, but heart rate increases have been observed. METHODS: A pooled post hoc analysis of 11 randomized clinical trials (N = 4595) of 10–30 weeks’ duration from the exenatide once-weekly (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marso, Steven P., Hardy, Elise, Han, Jenny, Wang, Hui, Chilton, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104267/ https://www.ncbi.nlm.nih.gov/pubmed/29397532 http://dx.doi.org/10.1007/s13300-018-0370-z

Ejemplares similares

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018)

Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment
por: Blevins, Thomas, et al.
Publicado: (2016)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study
por: Jabbour, Serge A., et al.
Publicado: (2018)

Once-Weekly Exenatide in Youth With Type 2 Diabetes
por: Tamborlane, William V., et al.
Publicado: (2022)

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
por: Chiquette, Elaine, et al.
Publicado: (2012)

Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials
por: van der Aart ‐ van der Beek, Annemarie B., et al.
Publicado: (2020)

Emerging utility of once-weekly exenatide in patients with type 2 diabetes
por: Goud, Aditya, et al.
Publicado: (2015)

Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
por: Inaishi, Jun, et al.
Publicado: (2022)

Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease
por: Guja, Cristian, et al.
Publicado: (2020)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study
por: Wysham, Carol H, et al.
Publicado: (2020)

Exenatide once weekly: clinical outcomes and patient satisfaction
por: Jose, Biju, et al.
Publicado: (2010)

Correction to: Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease
por: Guja, Cristian, et al.
Publicado: (2020)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
por: Watanabe, Yuusuke, et al.
Publicado: (2019)

Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
por: Blonde, Lawrence, et al.
Publicado: (2015)

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Seewoodhary, Jason, et al.
Publicado: (2010)

Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes
por: Grossman, Samuel S.
Publicado: (2014)

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
por: Mann, Katherine V, et al.
Publicado: (2014)

Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations
por: Pencek, R, et al.
Publicado: (2012)

Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives
por: Deng, Wuquan, et al.
Publicado: (2015)

Efficacy and safety of autoinjected exenatide once‐weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION‐NEO‐2 randomized clinical study
por: Gadde, Kishore M., et al.
Publicado: (2017)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years
por: Taylor, Kristin, et al.
Publicado: (2011)

A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes
por: Genovese, Stefano, et al.
Publicado: (2017)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
por: Ridge, T, et al.
Publicado: (2012)

Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial
por: Yammine, Luba, et al.
Publicado: (2018)

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis
por: Gaebler, Julia A, et al.
Publicado: (2012)

The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States
por: Wang, Bruce, et al.
Publicado: (2015)

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients
por: MacConell, Leigh, et al.
Publicado: (2015)

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
por: Buse, John B., et al.
Publicado: (2010)

Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
por: Diamant, Michaela, et al.
Publicado: (2012)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
por: Saunders, William B, et al.
Publicado: (2016)

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
por: MacConell, Leigh, et al.
Publicado: (2013)

Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study
por: Henry, Robert R., et al.
Publicado: (2016)

The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
por: Wang, Jie, et al.
Publicado: (2019)

Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
por: Meloni, Alison R, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nt2q0dvukl5fb5c86rcjqgkkm1